SUNNYVALE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- BioCardia ®, Inc. [NASDAQ:BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

With the ability to be coaxed into different kinds of mature cell types, induced pluripotent stem cells (iPSCs) hold all kinds of potential in the world of regenerative medicine. One of the many ...

The Japan cold laser therapy market is poised for significant growth, driven by advancements in medical technology and an increasing demand for non-invasive treatment options. The market, currently ...

The Japanese Ministry of Health, Labour, and Welfare (MHLW) has granted approval to Sarepta Therapeutics’ gene therapy Elevidys (delandistrogene moxeparvovec) for treating Duchenne muscular dystrophy ...

OCALA, Fla., Sept. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has issued a patent covering the ...

Reimbursement Review of Inspire Therapy Completed by Japan Ministry of Health Labour and Welfare (MHLW); National Health Insurance Payment Listing Expected in June 2021 Initial Inspire Therapy ...

CAMBRIDGE, Mass. - Sarepta Therapeutics, Inc. (NASDAQ:SRPT), currently trading near its 52-week low and down over 70% year-to-date according to InvestingPro data, announced the Japanese Ministry of ...

– Kite Cell Therapy Business Unit at Gilead Sciences K.K. Will Manage the Sales and Promotion Activities in Japan After the Marketing Authorization Transfer – SANTA MONICA, Calif. & TOKYO--(BUSINESS ...

– Daiichi Sankyo to Transfer Yescarta Marketing Authorization in Japan to Gilead Sciences K.K. – – Kite Cell Therapy Business Unit at Gilead Sciences K.K. Will Manage the Sales and Promotion ...

Ask analyst of customized report: https://www.imarcgroup.com/request?type=report&id=17931&flag=E Note: If you require specific details, data, or insights that are not ...